Synbiotics administration leads to attenuated mucosal inflammatory neutrophil infiltration and increased hematocrit in experimental ulcerative colitis

Objective: The objective of the study was to estimate the effects of synbiotics on laboratory, macroscopic, and histopathologic features in dextran sulfate sodium (DSS) experimental colitis. Materials and methods: A total of 40 Wistar rats received 5% of DSS in their drinking water for 8 days to induce ulcerative colitis (UC). Eight rats were sacrificed to confirm the presence of UC. The remaining rats were randomly assigned to two groups: the synbiotics group, which received synbiotics once per day and the control group, which received tap water for another 8 days. Results: On the 8th day of DSS administration animals developed UC with bloody diarrhea. In the majority of the hematologic variables studied (hemoglobin [HB], red blood cells, platelets, mean corpuscular volume, and mean corpuscular HB), in bodyweight and histopathologic colitis score there was no significant difference between groups. However, the synbiotics group, compared to control, presented a significantly greater colon length on the 4th day, significantly increased hematocrit (HT) on the 8th day, and a significantly decreased number of myeloperoxidase positive cells on the 8th day. Furthermore, there was a trend toward histopathological and clinical improvement. Conclusions: Administration of synbiotics in the experimental UC results in an attenuation of mucosal inflammatory neutrophil infiltration and an increase in HT.

[1]  M. Roselli,et al.  Use of Synbiotics for Ulcerative Colitis Treatment. , 2019, Current clinical pharmacology.

[2]  O. Ioannidis,et al.  The effect of glutamine and synbiotics on the healing of colonic anastomosis. , 2014, Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva.

[3]  O. Ioannidis,et al.  Artificial Nutrition and Intestinal Mucosal Barrier Functionality , 2013, Digestion.

[4]  I. Taitzoglou,et al.  Omega 3 fatty acids supplementation has an ameliorative effect in experimental ulcerative colitis despite increased colonic neutrophil infiltration. , 2011, Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva.

[5]  G. Paraskevas,et al.  Nutritional Modulation of the Inflammatory Bowel Response , 2011, Digestion.

[6]  L. Balart,et al.  Do probiotics have a role in the management of inflammatory bowel disease? , 2009, The Journal of the Louisiana State Medical Society : official organ of the Louisiana State Medical Society.

[7]  S. Tannenbaum,et al.  Nitric oxide and TNF-α trigger colonic inflammation and carcinogenesis in Helicobacter hepaticus-infected, Rag2-deficient mice , 2009, Proceedings of the National Academy of Sciences.

[8]  B. Ramakrishna,et al.  Probiotic administration alters the gut flora and attenuates colitis in mice administered dextran sodium sulfate , 2008, Journal of gastroenterology and hepatology.

[9]  L. Dieleman,et al.  Probiotics and Prebiotics as Functional Ingredients in Inflammatory Bowel Disease , 2008 .

[10]  F. Shanahan,et al.  Probiotic effects on inflammatory bowel disease. , 2007, The Journal of nutrition.

[11]  F. Cominelli,et al.  Probiotics in experimental and human inflammatory bowel disease: discussion points. , 2006, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[12]  S. Ahrné,et al.  Bifidobacterium infantis strains with and without a combination of Oligofructose and Inulin (OFI) attenuate inflammation in DSS-induced colitis in rats , 2006, BMC gastroenterology.

[13]  L. Dieleman,et al.  Probiotics and prebiotics in chronic inflammatory bowel diseases. , 2006, World journal of gastroenterology.

[14]  R. Bibiloni,et al.  VSL#3 Probiotic-Mixture Induces Remission in Patients with Active Ulcerative Colitis , 2005, The American Journal of Gastroenterology.

[15]  F. Shanahan,et al.  Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. , 2005, Gastroenterology.

[16]  M. Stolte,et al.  Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine , 2004, Gut.

[17]  R Balfour Sartor,et al.  Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. , 2004, Gastroenterology.

[18]  F. Shanahan.  Probiotics in inflammatory bowel disease--therapeutic rationale and role. , 2004, Advanced drug delivery reviews.

[19]  D. Podolsky,et al.  Functional modulation of enterocytes by gram-positive and gram-negative microorganisms. , 2004, American journal of physiology. Gastrointestinal and liver physiology.

[20]  P. Mangell,et al.  Bacterial translocation: impact of probiotics , 2004 .

[21]  F. Guarner,et al.  Role of bacteria in experimental colitis. , 2003, Best practice & research. Clinical gastroenterology.

[22]  P. Yen.  Probiotics and prebiotics for bowel health. , 2003, Geriatric nursing.

[23]  J. Fox,et al.  CD4+ CD25+ regulatory T lymphocytes inhibit microbially induced colon cancer in Rag2-deficient mice. , 2003, The American journal of pathology.

[24]  R. V. van Elburg,et al.  Intestinal permeability in relation to birth weight and gestational and postnatal age , 2003, Archives of disease in childhood. Fetal and neonatal edition.

[25]  G. Porro,et al.  Inflammatory bowel disease: new insights into pathogenesis and treatment , 2002, Journal of internal medicine.

[26]  K. Shiraki,et al.  Clinicopathological analysis of liver abscess in Japan. , 2002, International journal of molecular medicine.

[27]  M. Yamaguchi,et al.  Characterization of the increase in bone 66 kDa protein component with healing rat fractures: stimulatory effect of zinc. , 2002, International journal of molecular medicine.

[28]  J. Saavedra,et al.  Human studies with probiotics and prebiotics: clinical implications , 2002, British Journal of Nutrition.

[29]  R. Eliakim,et al.  Probiotics--scope and promise in inflammatory bowel disease. , 2002, The Israel Medical Association journal : IMAJ.

[30]  G. Reid,et al.  Use of Lactobacillus to prevent infection by pathogenic bacteria. , 2002, Microbes and infection.

[31]  C. De Simone,et al.  Probiotic bacteria enhance murine and human intestinal epithelial barrier function. , 2001, Gastroenterology.

[32]  P. Gionchetti,et al.  Expression of cytokines, inducible nitric oxide synthase, and matrix metalloproteinases in pouchitis: effects of probiotic treatment , 2001, American Journal of Gastroenterology.

[33]  F. Guarner,et al.  Dietary inulin improves distal colitis induced by dextran sodium sulfate in the rat , 2001, American Journal of Gastroenterology.

[34]  M. Sata,et al.  Prebiotic treatment of experimental colitis with germinated barley foodstuff: a comparison with probiotic or antibiotic treatment. , 2001, International journal of molecular medicine.

[35]  M. de Vrese,et al.  Probiotics, prebiotics, and synbiotics--approaching a definition. , 2001, The American journal of clinical nutrition.

[36]  A. Pfeifer,et al.  Non-pathogenic bacteria elicit a differential cytokine response by intestinal epithelial cell/leucocyte co-cultures , 2000, Gut.

[37]  R. Sartor,et al.  Lactobacillus GG prevents recurrence of colitis in HLA-B27 transgenic rats after antibiotic treatment , 2000, Gut.

[38]  P. Brigidi,et al.  Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis , 1999, Alimentary pharmacology & therapeutics.

[39]  A. Vetuschi,et al.  Dextran Sulfate Sodium (DSS) Colitis in Rats (Clinical, Structural, and Ultrastructural Aspects) , 1999, Digestive Diseases and Sciences.

[40]  G R Gibson,et al.  Probiotics, prebiotics, and synbiotics: approaches for modulating the microbial ecology of the gut. , 1999, The American journal of clinical nutrition.

[41]  K. Madsen,et al.  Lactobacillus species prevents colitis in interleukin 10 gene-deficient mice. , 1999, Gastroenterology.

[42]  E. Bloemena,et al.  Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines , 1998, Clinical and experimental immunology.

[43]  R. Berg,et al.  The indigenous gastrointestinal microflora. , 1996, Trends in microbiology.

[44]  M. Leach,et al.  Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. , 1996, The Journal of clinical investigation.

[45]  H. Cooper,et al.  Clinicopathologic study of dextran sulfate sodium experimental murine colitis. , 1993, Laboratory investigation; a journal of technical methods and pathology.

[46]  A. Onderdonk.  Experimental models for ulcerative colitis , 1985, Digestive Diseases and Sciences.

[47]  R. Farrell,et al.  Probiotics and Inflammatory Bowel Disease , 2012, BioDrugs.

[48]  L. Morelli,et al.  Probiotics, prebiotics, and new foods. , 2008, Journal of clinical gastroenterology.

[49]  T. Ohkusa,et al.  A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. , 1990, Gastroenterology.